A detailed history of Jpmorgan Chase & CO transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,564 shares of ENLV stock, worth $3,051. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,564
Previous 1,814 41.35%
Holding current value
$3,051
Previous $3,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025

BUY
$0.84 - $1.69 $630 - $1,267
750 Added 41.35%
2,564 $2,000
Q3 2024

Dec 26, 2024

BUY
$1.2 - $1.69 $1,899 - $2,675
1,583 Added 685.28%
1,814 $3,000
Q3 2024

Nov 08, 2024

BUY
$1.2 - $1.69 $1,899 - $2,675
1,583 Added 685.28%
1,814 $3,000
Q2 2024

Dec 26, 2024

SELL
$1.27 - $4.31 $2,010 - $6,822
-1,583 Reduced 87.27%
231 $0
Q2 2024

Aug 12, 2024

SELL
$1.27 - $4.31 $8,788 - $29,825
-6,920 Reduced 96.77%
231 $0
Q1 2024

Dec 26, 2024

BUY
$2.54 - $4.3 $13,555 - $22,949
5,337 Added 294.21%
7,151 $27,000
Q1 2024

May 10, 2024

BUY
$2.54 - $4.3 $17,561 - $29,730
6,914 Added 2917.3%
7,151 $27,000
Q4 2023

Dec 26, 2024

SELL
$1.29 - $2.92 $2,034 - $4,604
-1,577 Reduced 86.93%
237 $0
Q4 2023

Feb 12, 2024

SELL
$1.29 - $2.92 $1,242 - $2,811
-963 Reduced 80.25%
237 $0
Q3 2023

Nov 14, 2023

SELL
$1.46 - $2.97 $1,721 - $3,501
-1,179 Reduced 49.56%
1,200 $1,000
Q2 2023

Aug 11, 2023

BUY
$2.51 - $3.71 $5,790 - $8,558
2,307 Added 3204.17%
2,379 $6,000
Q1 2023

May 11, 2023

SELL
$3.41 - $4.55 $88 - $118
-26 Reduced 26.53%
72 $0
Q4 2022

Feb 13, 2023

BUY
$3.74 - $4.81 $366 - $471
98 New
98 $0
Q2 2022

Aug 11, 2022

SELL
$3.81 - $8.64 $4,389 - $9,953
-1,152 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$4.92 - $6.66 $5,667 - $7,672
1,152 New
1,152 $6,000

Others Institutions Holding ENLV

About Enlivex Therapeutics Ltd.


  • Ticker ENLV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,403,200
  • Market Cap $21.9M
  • Description
  • Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...
More about ENLV
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.